Mezzion Pharma Co.Ltd Net Assets
Mezzion Pharma Co.Ltd net assets. Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has net assets worth ₩39.04 Billion KRW (≈ $26.46 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩125.25 Billion ≈ $84.88 Million USD) and total liabilities (₩86.20 Billion ≈ $58.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Mezzion Pharma Co.Ltd (140410) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩39.04 Billion |
| % of Total Assets | 31.17% |
| Annual Growth Rate | -9.54% |
| 5-Year Change | -72.62% |
| 10-Year Change | -67.44% |
| Growth Volatility | 50.51 |
Net Assets of Mezzion Pharma Co.Ltd (2012–2025)
Net assets of Mezzion Pharma Co.Ltd from 2012 to 2025. This chart illustrates how Mezzion Pharma Co.Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 140410 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for Mezzion Pharma Co.Ltd (2012–2025)
The table below shows the annual net assets of Mezzion Pharma Co.Ltd from 2012 to 2025. For live market cap and overall valuation, see 140410 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩17.19 Billion ≈ $11.65 Million |
-62.67% |
| 2024-12-31 | ₩46.06 Billion ≈ $31.22 Million |
-25.03% |
| 2023-12-31 | ₩61.44 Billion ≈ $41.64 Million |
+134.16% |
| 2022-12-31 | ₩26.24 Billion ≈ $17.78 Million |
-58.21% |
| 2021-12-31 | ₩62.79 Billion ≈ $42.55 Million |
+10.53% |
| 2020-12-31 | ₩56.81 Billion ≈ $38.50 Million |
+32.64% |
| 2019-12-31 | ₩42.83 Billion ≈ $29.03 Million |
-25.28% |
| 2018-12-31 | ₩57.32 Billion ≈ $38.84 Million |
+7.80% |
| 2017-12-31 | ₩53.17 Billion ≈ $36.03 Million |
+0.68% |
| 2016-12-31 | ₩52.81 Billion ≈ $35.79 Million |
-15.55% |
| 2015-12-31 | ₩62.54 Billion ≈ $42.38 Million |
-1.26% |
| 2012-12-31 | ₩63.34 Billion ≈ $42.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mezzion Pharma Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 921.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Mezzion Pharma Co.Ltd Net Assets Breakdown (December 2025)
Mezzion Pharma Co.Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩195.32 Billion | 1135.96% |
| Total Equity | ₩17.19 Billion | 100.00% |
Mezzion Pharma Co.Ltd Competitors by Market Cap
The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wuhan Xingtu Xinke Electronics Co Ltd
SHG:688081
|
$333.22 Million |
|
Everyday Network
SHE:300295
|
$333.23 Million |
|
Ege Profil Ticaret ve Sanayi AS
IS:EGPRO
|
$333.24 Million |
|
Mobia Medical, Inc. Common Stock
NASDAQ:MOBI
|
$333.24 Million |
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
$332.96 Million |
|
Bsm Chemical Co Ltd
SHE:300796
|
$332.93 Million |
|
Planet Technology
TWO:6263
|
$332.78 Million |
|
Seanergy Maritime Holdings Corp
NASDAQ:SHIP
|
$332.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mezzion Pharma Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,062,511,800 to 17,194,549,710, a change of -28,867,962,090 (-62.7%).
- Net loss of 34,928,862,370 reduced equity.
- New share issuances of 4,356,831,720 increased equity.
- Other factors increased equity by 1,704,068,560.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-34.93 Billion | -203.14% |
| Share Issuances | ₩4.36 Billion | +25.34% |
| Other Changes | ₩1.70 Billion | +9.91% |
| Total Change | ₩- | -62.67% |
Book Value vs Market Value Analysis
This analysis compares Mezzion Pharma Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 101.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 24.07x to 101.63x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2388.50 | ₩57500.00 | x |
| 2017-12-31 | ₩2233.74 | ₩57500.00 | x |
| 2018-12-31 | ₩2225.90 | ₩57500.00 | x |
| 2019-12-31 | ₩1639.86 | ₩57500.00 | x |
| 2020-12-31 | ₩2129.43 | ₩57500.00 | x |
| 2021-12-31 | ₩2351.53 | ₩57500.00 | x |
| 2022-12-31 | ₩981.23 | ₩57500.00 | x |
| 2023-12-31 | ₩2076.71 | ₩57500.00 | x |
| 2024-12-31 | ₩1537.30 | ₩57500.00 | x |
| 2025-12-31 | ₩565.76 | ₩57500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mezzion Pharma Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -203.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -441.61%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 5.70x
- Recent ROE (-203.14%) is below the historical average (-48.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 3.77% | 27.75% | 0.13x | 1.06x | ₩-3.95 Billion |
| 2015 | 6.75% | 28.29% | 0.14x | 1.65x | ₩-2.03 Billion |
| 2016 | -24.59% | -148.38% | 0.09x | 1.82x | ₩-18.27 Billion |
| 2017 | -27.99% | -266.42% | 0.08x | 1.39x | ₩-20.20 Billion |
| 2018 | -32.93% | -98.89% | 0.25x | 1.31x | ₩-24.61 Billion |
| 2019 | -54.29% | -122.82% | 0.32x | 1.37x | ₩-27.53 Billion |
| 2020 | -24.34% | -48.30% | 0.38x | 1.33x | ₩-19.51 Billion |
| 2021 | -21.66% | -51.03% | 0.32x | 1.34x | ₩-19.88 Billion |
| 2022 | -138.33% | -118.13% | 0.57x | 2.06x | ₩-38.92 Billion |
| 2023 | -20.72% | -40.13% | 0.34x | 1.50x | ₩-18.87 Billion |
| 2024 | -42.28% | -226.17% | 0.12x | 1.61x | ₩-24.08 Billion |
| 2025 | -203.14% | -441.61% | 0.08x | 5.70x | ₩-36.65 Billion |
Industry Comparison
This section compares Mezzion Pharma Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $85,269,200,607
- Average return on equity (ROE) among peers: -2.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mezzion Pharma Co.Ltd (140410) | ₩39.04 Billion | 3.77% | 2.21x | $333.02 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $173.74 Billion | 3.36% | 1.15x | $2.91 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $37.74 Billion | 28.99% | 1.00x | $21.80 Million |
| NatureCell Co.Ltd (007390) | $60.85 Billion | -52.64% | 0.14x | $848.87 Million |
| Sam-A Pharm. Co. Ltd (009300) | $160.90 Billion | 5.47% | 0.08x | $56.62 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $211.72 Billion | 2.48% | 0.22x | $79.05 Million |
| WooGene B&G Co. Ltd (018620) | $21.90 Billion | 1.61% | 0.93x | $47.95 Million |
| Oscotec Inc (039200) | $21.78 Billion | -9.28% | 0.67x | $714.16 Million |
| EstechPharma Co. Ltd (041910) | $72.13 Billion | -1.21% | 0.27x | $45.36 Million |
| Komipharm International Co. Ltd (041960) | $60.02 Billion | -6.63% | 0.98x | $344.77 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $31.91 Billion | 4.87% | 0.56x | $25.83 Million |
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more